Related Experiment Video

Updated: May 20, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.0K

Small Molecule B-RAF Inhibitors as Anti-Cancer Therapeutics: Advances in Discovery, Development, and Mechanistic

Yamile Abuchard Anaya1,2,3,4, Ricardo Pequeno Bracho1,3,4, Subhash C Chauhan3,4

  • 1School of Integrative Biological and Chemical Sciences, The University of Texas Rio Grande Valley, 1201 West University Drive, Edinburg, TX 78539, USA.

International Journal of Molecular Sciences
|March 27, 2025
PubMed

Insights

Targeting BRAF mutations with inhibitors improves cancer therapy, but resistance is a challenge. Combination strategies and novel inhibitors are key to overcoming resistance and improving patient outcomes in BRAF- V600E-mutant cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • BRAF kinase is central to the MAPK pathway, regulating cell growth and survival.
  • BRAF V600E mutations drive various cancers, establishing BRAF as a critical therapeutic target.
  • Targeted BRAF inhibitors have advanced cancer treatment but face acquired resistance.

Purpose of the Study:

  • To review the molecular mechanisms of BRAF inhibitors.
  • To discuss therapeutic efficacy and resistance mechanisms.
  • To highlight combination strategies and emerging therapies for BRAF-mutant cancers.

Main Methods:

  • Literature review of BRAF inhibitor mechanisms.
  • Analysis of therapeutic efficacy and resistance pathways.
  • Exploration of current and future treatment strategies.

Main Results:

  • BRAF inhibitors like Vemurafenib and Dabrafenib show efficacy but resistance develops via MAPK reactivation, RAF dimerization, and alternative pathways.
  • Current standard of care combines BRAF and MEK inhibitors.
  • EGFR inhibitors and immune checkpoint blockades show promise in overcoming resistance.

Conclusions:

  • Combination therapies are crucial for enhancing treatment outcomes in BRAF-mutant cancers.
  • Emerging pan-BRAF and brain-penetrant inhibitors offer new hope for refractory cases.
  • Precision medicine, including genomic profiling and liquid biopsies, is vital for personalized BRAF-targeted therapy.
Keywords:
B-RAFB-RAF V600E mutationDabrafenibEncorafenibMAPK pathwayMEK inhibitorsRAF kinase inhibitorsVemurafenibcancer therapyclinical trialscolorectal cancercombination therapydrug resistancemelanomanon-small cell lung carcinomaoncologysmall molecule inhibitorsthyroid carcinoma

More Related Videos

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

910
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
3.9K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.1K